Stoke Therapeutics Inc (STOK) USD0.0001

Sell:$6.23Buy:$6.24$0.42 (6.32%)

NASDAQ:0.87%
Market closed | Prices delayed by at least 15 minutes
Sell:$6.23
Buy:$6.24
Change:$0.42 (6.32%)
Market closed | Prices delayed by at least 15 minutes
Sell:$6.23
Buy:$6.24
Change:$0.42 (6.32%)
Market closed | Prices delayed by at least 15 minutes

Company Information

About this company

Stoke Therapeutics, Inc. is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with ribonucleic acid (RNA)-based medicines. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. TANGO aims to restore missing proteins by increasing or stoking protein output from healthy genes, thus compensating for the non-functioning copy of the gene. The Company is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The Company’s initial focus is haploinsufficiency and diseases of the central nervous system and the eye.

Key people

Arthur O. Tzianabos
Interim Executive Chairman of the Board
Ian F. Smith
Chief Executive Officer, Director
Thomas Leggett
Chief Financial Officer
Jonathan Allan
General Counsel, Corporate Secretary
Jason Hoitt
Chief Commercial Officer
Eric Olson
Chief Business Officer
Barry S. Ticho
Chief Medical Officer
Edward M. Kaye
Director
Jennifer C. Burstein
Independent Director
Seth L. Harrison
Independent Director
Adrian R. Krainer
Independent Director
Arthur A. Levin
Independent Director
Click to see more

Key facts

  • EPIC
    STOK
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US86150R1077
  • Market cap
    $389.90m
  • Employees
    128
  • Shares in issue
    54.08m
  • Exchange
    NASDAQ
  • Index
    TR Equity United States Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.